Redhill Biopharma (RDHL) Competitors $2.19 +0.06 (+2.82%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$2.15 -0.04 (-1.78%) As of 07/11/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CARM, MRKR, CTXR, RVPH, PMN, GOVX, PRPH, ALLR, HOTH, and LEXXShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs ProPhase Labs Allarity Therapeutics Hoth Therapeutics Lexaria Bioscience Carisma Therapeutics (NASDAQ:CARM) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership. Which has more volatility and risk, CARM or RDHL? Carisma Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.22, meaning that its share price is 322% more volatile than the S&P 500. Is CARM or RDHL more profitable? Redhill Biopharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Redhill Biopharma N/A N/A N/A Does the media prefer CARM or RDHL? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 1 articles in the media. Redhill Biopharma's average media sentiment score of 1.87 beat Carisma Therapeutics' score of 0.93 indicating that Redhill Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Positive Redhill Biopharma Very Positive Do institutionals & insiders hold more shares of CARM or RDHL? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate CARM or RDHL? Carisma Therapeutics presently has a consensus price target of $1.93, suggesting a potential upside of 381.25%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, CARM or RDHL? Redhill Biopharma has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.85-$60.48M-$1.56-0.26Redhill Biopharma$8.04M0.63-$8.27MN/AN/A SummaryCarisma Therapeutics beats Redhill Biopharma on 8 of the 13 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.89M$2.74B$5.62B$9.09BDividend YieldN/A1.79%5.24%4.00%P/E RatioN/A9.4228.1320.27Price / Sales0.63714.13428.2698.57Price / CashN/A165.3637.4658.16Price / Book-0.604.608.045.49Net Income-$8.27M$31.26M$3.18B$250.45M7 Day Performance8.68%4.80%3.62%4.79%1 Month Performance12.89%5.42%4.06%7.68%1 Year Performance-99.10%-4.36%30.01%16.43% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$2.19+2.8%N/A-99.1%$4.89M$8.04M0.00210Positive NewsCARMCarisma Therapeutics3.1506 of 5 stars$0.39-2.2%$1.93+391.6%-66.7%$16.74M$19.63M-0.2520MRKRMarker Therapeutics4.6605 of 5 stars$1.53+4.8%$13.17+760.6%-64.8%$16.52M$6.59M-1.1560News CoveragePositive NewsGap UpCTXRCitius Pharmaceuticals3.1753 of 5 stars$1.59+3.9%$53.00+3,233.3%-91.9%$16.27MN/A0.0020High Trading VolumeRVPHReviva Pharmaceuticals3.0866 of 5 stars$0.38+12.9%$9.00+2,261.6%-69.2%$16.20MN/A-0.485Gap UpHigh Trading VolumePMNPromis Neurosciences3.361 of 5 stars$0.48+0.7%$4.50+830.1%-81.5%$15.70MN/A-9.685Positive NewsGap UpGOVXGeoVax Labs2.3022 of 5 stars$0.87-9.8%$11.10+1,182.2%-76.7%$15.29M$3.95M-0.2410Analyst RevisionPRPHProPhase Labs0.6795 of 5 stars$0.39+6.6%N/A-87.8%$15.25M$6.77M-0.31130Gap UpALLRAllarity Therapeutics0.6698 of 5 stars$1.01+1.0%N/A-83.1%$15.08MN/A0.0010Gap DownHOTHHoth Therapeutics2.863 of 5 stars$1.17+3.5%$4.00+241.9%+58.2%$14.93MN/A-1.034LEXXLexaria Bioscience2.3473 of 5 stars$0.87+2.5%$7.00+704.6%-68.7%$14.91M$460K-1.477 Related Companies and Tools Related Companies Carisma Therapeutics Competitors Marker Therapeutics Competitors Citius Pharmaceuticals Competitors Reviva Pharmaceuticals Competitors Promis Neurosciences Competitors GeoVax Labs Competitors ProPhase Labs Competitors Allarity Therapeutics Competitors Hoth Therapeutics Competitors Lexaria Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts